Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the third in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).